Onyx Biotec Past Earnings Performance

Past criteria checks 3/6

Onyx Biotec has been growing earnings at an average annual rate of 64.4%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 36.1% per year. Onyx Biotec's return on equity is 12.2%, and it has net margins of 5.6%.

Key information

64.4%

Earnings growth rate

62.5%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate36.1%
Return on equity12.2%
Net Margin5.6%
Last Earnings Update31 Mar 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Onyx Biotec makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:ONYX Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2453730600
31 Mar 23395181050
31 Mar 2244934870

Quality Earnings: ONYX has high quality earnings.

Growing Profit Margin: ONYX's current net profit margins (5.6%) are higher than last year (4.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ONYX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare ONYX's past year earnings growth to its 5-year average.

Earnings vs Industry: ONYX earnings growth over the past year (64.4%) exceeded the Pharmaceuticals industry 20.5%.


Return on Equity

High ROE: ONYX's Return on Equity (12.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies